The Netherlands’ new Health Minister has hit out at “absurd” drug prices, suggesting that the use of compulsory patent licensing might be one solution. This comes shortly after Germany’s highest court upheld a landmark decision forcing a life sciences innovator to license a key patent to a competitor.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Straight talk on key IP issues, IAM aims to provide executive managers with the business perspective that often gets lost in technical jargon and legal details.

Gene Potkay
Senior vice president of intellectual property
The Nielsen Company

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?